IP Library Granted Patent US 9,649,368
Granted Patent B2
US 9,649,368 · App. 15/091,509 · Granted May 16, 2017

Genetically engineered microbial strains including prototheca lipid pathway genes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,649,368
App. No.
15/091,509
Granted
May 16, 2017
Kind
B2
Abstract

Genetically engineered microbial, e.g., Prototheca , cells provide microbial oil useful as a food additive and a source of renewable fuels and industrial chemicals.

Claims (12)

1. A recombinant nucleic acid comprising a coding sequence that encodes a Prototheca glycerol-3-phosphate acyltransferase (GPAT) having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 225 and having GPAT activity, wherein said coding sequence is operably linked to a heterologous nucleic acid sequence.

2. The recombinant nucleic acid of claim 1 , wherein said GPAT comprises at least one amino acid substitution in comparison to the amino acid sequence of SEQ ID NO: 225, and has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 225 and has GPAT activity.

3. The recombinant nucleic acid of claim 1 , wherein said nucleic acid sequence comprises a promoter.

4. The recombinant nucleic acid of claim 1 , wherein said heterologous nucleic acid sequence comprises an untranslated control element.

5. The recombinant nucleic acid of claim 1 , wherein said heterologous nucleic acid sequence encodes a targeting sequence.

6. The recombinant nucleic acid of claim 5 , wherein said targeting sequence is a transit peptide selected from the group consisting of a plastidial targeting sequence and a mitochondrial targeting sequence.

7. The recombinant nucleic acid of claim 1 , wherein said nucleic acid is a DNA molecule.

8. The recombinant nucleic acid of claim 1 , further encoding a sucrose invertase.

9. The recombinant nucleic acid of claim 1 , further encoding an inhibitory RNA that suppresses expression of a Prototheca lipid biosynthesis gene.

10. An expression cassette comprising the recombinant nucleic acid of claim 1 .

11. A genetically engineered microbial cell transformed with the recombinant nucleic acid of claim 1 .

12. A method for obtaining microbial oil comprising culturing the genetically engineered microbial cell of claim 11 under conditions wherein oil is produced, wherein said genetically engineered microbial cell is a genetically engineered Prototheca cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2017
From: TERRAVIA HOLDINGS, INC.
To: CORBION BIOTECH, INC.
Reel/Frame 044424/0211 →
CHANGE OF NAME Recorded May 23, 2016
From: SOLAZYME, INC.
To: TERRAVIA HOLDINGS, INC.
Reel/Frame 038794/0867 →